They reviewed 227 EGFR-TKI refractory NSCLC patients and reported that the post-progression survival (PPS) was significantly longer in patients who received rebiopsy and treatment based on a resistant mechanism (n = 70, median PPS 24.2 months) than those who received rebiopsy and salvage regimen (n = 37, median PPS 15.2 months, p = 0.002) and who did not receive rebiopsy (n = 120, median PPS 9.7 months, p < 0.001). This evidence concerns the gene EGFR and non-small cell lung carcinoma.